Bimetinib for the treatment of melanoma: Should the drug be discontinued if the rash is severe?

Binimetinib is a MEK inhibitor mainly used to treat unresectable or metastatic melanoma with BRAF V600 mutations. It is usually combined with a BRAF inhibitor to achieve a synergistic anti-cancer effect. As a targeted therapy drug, bimetinib is more specific than traditional chemotherapy, but it may also cause a series of target-related skin side effects, the most common of which is rash. Skin rash not only affects the patient's quality of life, but may also become an important indicator in deciding whether to continue taking medication.

The rash associated with MEK inhibitors usually presents as maculopapular, acneiform or erythematous rash. The onset time is usually 1-2 weeks in the initial period of treatment, and may gradually worsen as the course of treatment is extended. Some patients' rash is accompanied by itching and burning sensations, and even occurs on exposed parts such as the face, chest and back, causing significant psychological stress to the patients. Although most rashes are mild to moderate and can be relieved with topical or oral antihistamines, a high level of caution is needed if the rash becomes severe, accompanied by extensive peeling, blistering, or secondary infection.

When it comes to whether medication needs to be discontinued, medical guidelines generally recommend a graded approach based on the severity of the rash. For mild rashes of grade 1-2, it is feasible to continue treatment and cooperate with symptomatic treatment; for severe rashes of grade 3 or above, especially those that affect daily life or have large areas of skin damage, it is recommended to suspend bimetinib treatment and consider taking oral steroids, strengthening skin protection, and specialist consultation. After the rash symptoms improve or return to below grade 1, you can try to restart treatment under the guidance of a doctor and adjust the dose according to tolerance.

It is worth mentioning that some patients may become dependent on the efficacy of bimetinib combined with BRAF inhibitors and are unwilling to discontinue the drug easily even if side effects occur. In this case, the benefits of tumor control should be weighed against the risk of adverse skin reactions, and treatment should be maintained in a manner that minimizes discomfort while enhancing skin care and nutritional support.

Reference materials:https://go.drugbank.com/drugs/DB11967